TRANSPLANTATION OF SUBRETINAL STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM FOR STARGARDT'S DISEASE: A PHASE I CLINICAL TRIAL.

Rodrigo Antonio Brant FernandesFernando H LojudiceLucas Zago RibeiroNatasha Ferreira Santos da CruzMurilo Ubukata PolizelliPriscila C CristovamFrancesco InnocentiLisangela MorimotoOctaviano MagalhãesJuliana Maria Ferraz SallumErnando Marcondes PenhaMari C SogayarRubens BelfortMauricio Maia

Published in: Retina (Philadelphia, Pa.) (2022)

This surgical procedure was feasible and safe without cellular migration, rejection, inflammation, or development of ocular or systemic tumors during follow-up.

Keyphrases

clinical trial
oxidative stress
minimally invasive
phase ii
open label
double blind
study protocol
cell therapy
stem cells
bone marrow
placebo controlled